Effects of Bisphosphonates on OI-Related Hearing Loss

  • STATUS
    Recruiting
  • End date
    Nov 24, 2024
  • participants needed
    100
  • sponsor
    Hospital for Special Surgery, New York
Updated on 24 April 2022
hearing loss
vitamin d
bisphosphonate
risedronate oral tablet
Accepts healthy volunteers

Summary

Osteogenesis Imperfecta-related hearing loss usually occurs in individuals with mild (type I) OI and is much earlier in onset than age-related hearing loss, with the majority of individuals experiencing some minor hearing loss in their 20s. Bisphosphonates have been successfully used to treat otosclerosis, a common cause of hearing loss similar to OI-related hearing loss. As many individuals with OI-related hearing loss also present with otosclerosis and because of their mechanistic similarities, the investigators propose studying the effects of bisphosphonate treatment on individuals diagnosed with both OI type I and hearing loss, thereby determining its effectiveness as a potential treatment for hearing loss.

The investigators will enroll 50 individuals diagnosed with type I OI and age 18-100. 25 adults will be enrolled into the treatment arm and receive bisphosphonate treatment (must have at least mild hearing loss), while 25 adults will be enrolled into the control arm. The investigators will enroll 25 children (6-17 years of age) diagnosed with OI who are currently receiving bisphosphonate treatment as part of their care for orthopedic symptoms. The investigators will also observe 25 children (6-17 years of age) diagnosed with OI who are NOT currently receiving bisphosphonate treatment. The study duration is 63 months (approximately 5 years). Enrollment is anticipated to begin in November 2019.

Details
Condition Osteogenesis Imperfecta
Treatment Risedronate Oral Tablet
Clinical Study IdentifierNCT04152551
SponsorHospital for Special Surgery, New York
Last Modified on24 April 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Diagnosis of OI type I
Diagnosis of at least mild hearing loss (>20dB pure tone average) by audiogram testing
+
Vitamin D level > 30
Diagnosis of OI
Inclusion Criteria (Adult Control Arm)
Age 6-17 years
Diagnosis of OI type I
Inclusion Criteria (Child Observational Bisphosphonate Arm)
Diagnosis of OI
Age 6-17 years
NOT receiving bisphosphonate treatment and will not receive bisphosphonate treatment for the duration of the study
Currently receiving bisphosphonate treatment as standard of care
Inclusion Criteria (Child Observational No Treatment Arm)

Exclusion Criteria

Family history of hearing-loss (not related to OI or occupational hearing loss)
Pregnancy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note